The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.
Zuppa, A. A., Cardiello, V., Alighieri, G., Cota, F., D'Antuono, A., Riccardi, R., Catenazzi, P., Romagnoli, C., Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia, <<JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY>>, 2012; (Oct 15): N/A-N/A [http://hdl.handle.net/10807/39803]
Anti-Rh(c), "Little C," Isoimmunization: The Role of rHuEpo in Preventing Late Anemia
Zuppa, Antonio Alberto;Cardiello, Valentina;Alighieri, Giovanni;Cota, Francesco;D'Antuono, Annamaria;
2012
Abstract
The overall prevalence of non-Rh-D isoimmunization seems to lie between 0.15% and 1.1%. Anti-Rh(c) alloimmunization, "little c," occurs in 0.07% of pregnancies and shows a quite broad clinical presentation. Late anemia is a frequent problem occurring in the setting of isoimmunization. It occurs more frequently after intrauterine blood transfusions or exsanguinotransfusion, and it can be thought as a hyporegenerative anemia. The authors describe the use of human recombinant erythropoietin in preventing late anemia in a case of anti-Rh(c) isoimmunization. The use of human recombinant erythropoietin is a valid tool for preventing late-onset anemia due to either anti-Rh-D or non-anti-Rh-D isoimmunization.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
